NCT03163368
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Early Phase 1
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have at least one brain lesion less than or equal to 40 mm in diameter that is suitable for surgical resection and stereotactic radiotherapy
Exclusions: Patients with leptomeningeal disease; Patients with more than 4 brain metastases
https://ClinicalTrials.gov/show/NCT03163368